AEMD
Aethlon Medical, Inc.

James "Jim" Joyce has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership roles. He is also an inventor or co-inventor underlying 18 pending or issued patents. Prior to establishing Sigyn Therapeutics, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, a therapeutic technology company that he navigated from single shareholder start-up to Nasdaq-traded Company with 8000+ shareholders. During his tenure at Aethlon, Mr. Joyce oversaw the development of the Hemopurifier, a first-in-class blood purification technology to address life-threatening viruses and cancer-promoting exosomes. Under his leadership, the Hemopurifier became the first therapeutic candidate to be awarded two FDA "Breakthrough Device" designations and was the first and only device to receive "Emergency Use Authorization" (EAU) approval from both the FDA and Health Canada to treat Ebola virus. Time Magazine named the Hemopurifier one of the "11 Most Remarkable Advances in Healthcare and designated the device to its "Top 25 Best Inventions" award list. Mr. Joyce is also the founder and former Executive Chairman of Exosome Sciences, Inc. (ESI), a company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders.

James "Jim" Joyce has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership roles. He is also an inventor or co-inventor underlying 18 pending or issued patents. Prior to establishing Sigyn Therapeutics, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, a therapeutic technology company that he navigated from single shareholder start-up to Nasdaq-traded Company with 8000+ shareholders. During his tenure at Aethlon, Mr. Joyce oversaw the development of the Hemopurifier, a first-in-class blood purification technology to address life-threatening viruses and cancer-promoting exosomes. Under his leadership, the Hemopurifier became the first therapeutic candidate to be awarded two FDA "Breakthrough Device" designations and was the first and only device to receive "Emergency Use Authorization" (EAU) approval from both the FDA and Health Canada to treat Ebola virus. Time Magazine named the Hemopurifier one of the "11 Most Remarkable Advances in Healthcare and designated the device to its "Top 25 Best Inventions" award list. Mr. Joyce is also the founder and former Executive Chairman of Exosome Sciences, Inc. (ESI), a company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders.